Drug Profile
Research programme: glycan-binding biopharmaceuticals - ProtAffin Biotechnologie
Alternative Names: MCP-1 programme - ProtAffin; Oncology programme - ProtAffin; PA508; SDF-1α programme - ProtAffinLatest Information Update: 04 Sep 2013
Price :
$50
*
At a glance
- Originator ProtAffin Biotechnologie
- Class Proteins
- Mechanism of Action Glycosaminoglycan inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Coronary artery restenosis; Diabetic retinopathy; Fibrosis; Multiple sclerosis; Myocardial infarction; Uveitis